Chris James Rose1,2, James P. O'Connor1,2, Alan Jackson1,2, Yvon Watson1,2, Fran Maders3, Brandon J. Whitcher4, Caleb Roberts1,2, Giovanni A. Buonaccorsi1,2, Gerard Thompson1,2, Andrew R. Clamp3,5, Gordon C. Jayson5, Geoffrey J. Parker1,2
1The University of Manchester Biomedical Imaging Institute, The University of Manchester, Manchester, Greater Manchester, United Kingdom; 2Manchester Academic Health Science Centre, The University of Manchester, Manchester, Greater Manchester, United Kingdom; 3Department of Radiology, Christie Hospital, Manchester, Greater Manchester, United Kingdom; 4GlaxoSmithKline Clinical Imaging Centre, Hammersmith Hospital, Imperial College London, London, Greater London, United Kingdom; 5Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, Greater Manchester, United Kingdom
Current and emerging cancer therapies may facilitate dramatic improvements in survival but are expensive and patient response is variable. Being able to identify patients who will benefit could dramatically improve patient outcomes and decrease costs to healthcare providers. We report a retrospective analysis where we model the reduction in volume of CRC liver metastases after treatment with bevacizumab and FOLFOX6 using pre-treatment DCE-MRI-derived biomarkers of microvascular structure and function. Post-treatment tumour volume can be predicted from pre-treatment imaging data with median error of 12%; we interpret our results to explain tumour response in terms of drug penetration and accumulation.